PCH
ARQT icon

Polar Capital Holdings’s Arcutis Biotherapeutics ARQT Stock Holding History

Polar Capital Holdings’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$134M Buy
5,666,940
+110,771
+2% +$2.83M 0.47% 54
2025
Q4 		$161M Buy
5,556,169
+257,415
+5% +$6.59M 0.62% 41
2025
Q3 		$99.9M Buy
5,298,754
+292,279
+6% +$4.61M 0.48% 60
2025
Q2 		$70.2M Sell
5,006,475
-1,700,000
-25% -$23.8M 0.37% 71
2025
Q1 		$105M Sell
6,706,475
-670,906
-9% -$9.45M 0.64% 45
2024
Q4 		$103M Buy
7,377,381
+493,009
+7% +$5.4M 0.57% 50
2024
Q3 		$64M Buy
6,884,372
+5,300
+0.1% +$52.3K 0.31% 69
2024
Q2 		$64M Sell
6,879,072
-6,850
-0.1% -$61.9K 0.38% 71
2024
Q1 		$68.2M Buy
6,885,922
+588,234
+9% +$4.39M 0.36% 70
2023
Q4 		$20.3M Buy
6,297,688
+3,179,744
+102% +$8.64M 0.12% 133
2023
Q3 		$16.6M Sell
3,117,944
-9,833
-0.3% -$83.6K 0.12% 150
2023
Q2 		$29.8M Sell
3,127,777
-7,736
-0.2% -$85.9K 0.15% 121
2023
Q1 		$34.5M Buy
3,135,513
+1,129,736
+56% +$16.3M 0.22% 108
2022
Q4 		$29.7M Buy
2,005,777
+696,509
+53% +$12.2M 0.24% 116
2022
Q3 		$25K Sell
1,309,268
-96,528
-7% -$2.19M 0.16% 122
2022
Q2 		$30K Sell
1,405,796
-378,209
-21% -$7.76M 0.18% 113
2022
Q1 		$34.4K Hold
1,784,005
– – 0.16% 118
2021
Q4 		$37K Buy
1,784,005
+235,104
+15% +$4.68M 0.14% 122
2021
Q3 		$37K Sell
1,548,901
-133,642
-8% -$3.05M 0.15% 120
2021
Q2 		$45.9K Buy
1,682,543
+125,000
+8% +$3.52M 0.2% 107
2021
Q1 		$45.1M Buy
1,557,543
+782,543
+101% +$24.4M 0.28% 94
2020
Q4 		$21.8M Buy
+775,000
New +$19M 0.13% 149

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Polar Capital Holdings's ARQT Position: Q1 2026 in Review

Polar Capital Holdings increased its Arcutis Biotherapeutics (ARQT) stake by 2% in Q1 2026, buying an estimated $2.83M and bringing the position to 5,666,940 shares worth $134M. The position accounts for 0.47% of the portfolio, ranked #54.

Polar Capital Holdings first reported a position in ARQT in Q4 2020 and has held it in 22 quarters since. The position peaked at $161M in Q4 2025. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Polar Capital Holdings held 5,666,940 shares of Arcutis Biotherapeutics worth $134M as of Q1 2026.
  • Polar Capital Holdings bought 110,771 Arcutis Biotherapeutics shares in Q1 2026, an estimated $2.83M.
  • Arcutis Biotherapeutics made up 0.47% of Polar Capital Holdings's portfolio in Q1 2026, its #54 holding.
  • Polar Capital Holdings first reported a position in Arcutis Biotherapeutics in Q4 2020 and has held it in 22 quarters since.
  • Polar Capital Holdings's Arcutis Biotherapeutics position peaked at $161M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Polar Capital Holdings's 13F filing for Q1 2026, filed 15 May 2026.